Table 4.
Detection rate and location of recurrence in patients without treatment between radical prostatectomy and gallium‐68 prostate‐specific membrane antigen positron‐emission tomography/CT at different PSA values.
| Emmett (2017) 36 | Van Leeuwen (2016) 30 | Boreta (2019) 34 | |
|---|---|---|---|
| PSA range | 0.01–0.19 | 0.01–0.19 | 0.01–0.19 |
| Total patients (total positive, percentage positive) | 77 (45, 58.4%) | 35 (11, 31.4%) | 9 (3, 33.3%) |
| Recurrence fossa only | 12 | 5 | 0 |
| Pelvic lymph nodes ± fossa | 16 | 4 | 2 |
| Distant metastases ± fossa | 17 | 2 | 1 |
| PSA range | 0.2–0.49 | 0.2–0.49 | 0.20–0.59 |
| Total patients (total positive; % positive) | 82 (56; 68.3) | 28 (18; 64.3) | 80 (39; 48.8) |
| Recurrence fossa only | 22 | 10 | 6 |
| Pelvic lymph nodes ± fossa | 23 | 5 | 22 |
| Distant metastases ± fossa | 12 | 3 | 11 |
| PSA range | 0.50 to <1.0 | 0.5 to <1.0 | 0.60–1.19 |
| Total patients (total positive; % positive) | 25 (19; 76.0) | 7 (4; 57.1) | 24 (13; 54.2) |
| Recurrence fossa only | 9 | 5 | 2 |
| Pelvic lymph nodes ± fossa | 6 | 1 | 4 |
| Distant metastases ± fossa | 4 | 1 | 7 |